EGFR and carcinoma: Despite the EGFR mutation rate of 12.1% (8/66) reported by Chang et al., only one patient was detected with a sensitizing EGFR mutation—an EGFR exon 19 deletion; all the other 11 EGFR mutations detected in 7 pulmonary lymphoepithelioma-like carcinoma patients located in exons 18–21 are uncommon mutations with no evidence of therapeutic response to EGFR inhibitors [4, 23, 24].